{"entity":{"id":"nct07522073","kind":"trial","name":"A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma","aka":["DAWN-303"],"tldr":"A phase 3 trial testing INCB161734 in pancreatic ductal adenocarcinoma, now recruiting.","summary":"A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma is a phase 3 interventional study registered as NCT07522073, led by Incyte with Qiagen Manchester, and recruiting on the registry. Official title: A Randomised, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303). Planned enrolment is 588 participants (estimated). The study started in 2026-04-09 and primary completion is expected in 2028-09-15. No results have been posted on ClinicalTrials.gov.","status":"recruiting","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT07522073","url":"https://clinicaltrials.gov/study/NCT07522073"}],"tags":["ctgov-ingest"],"related":[],"cancers":["pancreatic","metastatic-pdac"],"sections":[],"technologies":[],"targets":[],"drugs":["incb161734"],"companies":["incyte"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07522073","phase":"3","setting":"A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)","sponsor":"Incyte","participation":[{"nct":"NCT07522073","source":"https://clinicaltrials.gov/study/NCT07522073","fetchedAt":"2026-10-07T16:55:48.292Z","studySha256":"c343f2c7783639e6dd7e3996d560f5e220c7d642b3541de6a44bf5c899d2945c","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-22","leadSponsor":"Incyte Corporation","collaboratorCount":1,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":588,"enrolmentType":"ESTIMATED","siteCount":228,"recruitingSiteCount":60,"countries":["Australia","Austria","Belgium","Canada","Denmark","Finland","France","Georgia","Germany","Italy","Japan","Netherlands","New Zealand","Norway","Poland","Puerto Rico","South Korea","Spain","Sweden","Switzerland","United Kingdom","United States"]}],"started":"2026-04-09","startedType":"actual","enrolled":588,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07522073/","neighbours":{"cancer":[{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"drug":[{"id":"incb161734","kind":"drug","name":"INCB161734","route":"/drugs/incb161734/"}],"company":[{"id":"incyte","kind":"company","name":"Incyte","route":"/companies/incyte/"}],"roadmap":[{"id":"pancreatic-roadmap","kind":"roadmap","name":"Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question","route":"/roadmaps/pancreatic-roadmap/"}],"idea":[{"id":"idea-pdac-ras-inhibitor-combinations-and-sequencing","kind":"idea","name":"RAS inhibitor combinations and sequence: pan-RAS plus G12D-selective, plus chemotherapy, and what to give after progression","route":"/ideas/idea-pdac-ras-inhibitor-combinations-and-sequencing/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}